Balance Sheet
Cash Flow Statement
AmortizationAmortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Cash from Investing Activities (2019 - 2025)

Historic Cash from Investing Activities for Legend Biotech (LEGN) over the last 7 years, with Q3 2025 value amounting to -$20.0 million.

  • Legend Biotech's Cash from Investing Activities fell 10607.79% to -$20.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$16.7 million, marking a year-over-year increase of 9529.04%. This contributed to the annual value of -$850.5 million for FY2024, which is 101667.28% down from last year.
  • Latest data reveals that Legend Biotech reported Cash from Investing Activities of -$20.0 million as of Q3 2025, which was down 10607.79% from -$165.5 million recorded in Q2 2025.
  • Legend Biotech's 5-year Cash from Investing Activities high stood at $407.5 million for Q4 2023, and its period low was -$695.6 million during Q2 2024.
  • In the last 5 years, Legend Biotech's Cash from Investing Activities had a median value of -$87.8 million in 2024 and averaged -$65.8 million.
  • The largest annual percentage gain for Legend Biotech's Cash from Investing Activities in the last 5 years was 153448.18% (2023), contrasted with its biggest fall of 480727.27% (2023).
  • Legend Biotech's Cash from Investing Activities (Quarter) stood at -$195.0 million in 2021, then skyrocketed by 112.79% to $24.9 million in 2022, then skyrocketed by 1534.48% to $407.5 million in 2023, then plummeted by 121.56% to -$87.8 million in 2024, then surged by 77.23% to -$20.0 million in 2025.
  • Its Cash from Investing Activities stands at -$20.0 million for Q3 2025, versus -$165.5 million for Q2 2025 and $256.6 million for Q1 2025.